Tanriover, M.D.; Aydin, O.A.; Guner, R.; Yildiz, O.; Celik, I.; Doganay, H.L.; Kose, S.; Akhan, S.; Akalin, E.H.; Sezer, Z.;
et al. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines 2022, 10, 1865.
https://doi.org/10.3390/vaccines10111865
AMA Style
Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, Kose S, Akhan S, Akalin EH, Sezer Z,
et al. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines. 2022; 10(11):1865.
https://doi.org/10.3390/vaccines10111865
Chicago/Turabian Style
Tanriover, Mine Durusu, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer,
and et al. 2022. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial" Vaccines 10, no. 11: 1865.
https://doi.org/10.3390/vaccines10111865
APA Style
Tanriover, M. D., Aydin, O. A., Guner, R., Yildiz, O., Celik, I., Doganay, H. L., Kose, S., Akhan, S., Akalin, E. H., Sezer, Z., Ozdarendeli, A., Unal, S., & on behalf of the TURKOVAC Study Group.
(2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines, 10(11), 1865.
https://doi.org/10.3390/vaccines10111865
